Grifols has announced that its anti-SARS-CoV-2 hyperimmune globulin has started a clinical trial to test its safety, efficacy and tolerability. This medicine provides a consistent concentration of purified neutralizing antibodies and could be used for both prevention and treatment of the disease. The clinical trial is the latest phase of an initiative that goes back to March when Grifols started work on its anti-SARS-CoV-2 hyperimmune globulin as part of a collaboration with U.S. government agencies.